Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone

Wang, Qing; Young, Jim; Bernasconi, Enos; Vernazza, Pietro; Calmy, Alexandra; Cavassini, Matthias; Furrer, Hansjakob; Fehr, Jan; Bucher, Heiner C; Battegay, Manuel; Swiss Hiv Cohort Study, SHCS (2014). Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. HIV clinical trials, 15(3), pp. 92-103. Thomas Land Publishers 10.1310/hct1503-92

Full text not available from this repository.

Background: Atazanavir boosted with ritonavir (ATV/r) and efavirenz (EFV) are both recommended as first-line therapies for HIV-infected patients. We compared the 2 therapies for virologic efficacy and immune recovery. Methods: We included all treatment-naïve patients in the Swiss HIV Cohort Study starting therapy after May 2003 with either ATV/r or EFV and a backbone of tenofovir and either emtricitabine or lamivudine. We used Cox models to assess time to virologic failure and repeated measures models to assess the change in CD4 cell counts over time. All models were fit as marginal structural models using both point of treatment and censoring weights. Intent-to-treat and various as-treated analyses were carried out: In the latter, patients were censored at their last recorded measurement if they changed therapy or if they were no longer adherent to therapy. Results: Patients starting EFV (n = 1,097) and ATV/r (n = 384) were followed for a median of 35 and 37 months, respectively. During follow-up, 51% patients on EFV and 33% patients on ATV/r remained adherent and made no change to their first-line therapy. Although intent-to-treat analyses suggest virologic failure was more likely with ATV/r, there was no evidence for this disadvantage in patients who adhered to first-line therapy. Patients starting ATV/r had a greater increase in CD4 cell count during the first year of therapy, but this advantage disappeared after one year. Conclusions: In this observational study, there was no good evidence of any intrinsic advantage for one therapy over the other, consistent with earlier clinical trials. Differences between therapies may arise in a clinical setting because of differences in adherence to therapy.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology
UniBE Contributor:	Furrer, Hansjakob
Subjects:	600 Technology > 610 Medicine & health
ISSN:	1528-4336
Publisher:	Thomas Land Publishers
Language:	English
Submitter:	Annelies Luginbühl
Date Deposited:	09 Oct 2014 11:17
Last Modified:	05 Dec 2022 14:35
Publisher DOI:	10.1310/hct1503-92
PubMed ID:	24947533
Uncontrolled Keywords:	CD4, antiretroviral therapy, epidemiology, protease inhibitors, reverse transcriptase inhibitors, viral load
URI:	https://boris.unibe.ch/id/eprint/54036